Agilent Technologies falls after Jefferies cuts PT on near-term uncertainty

Medical equipment maker Agilent Technologies' A.N shares down 2.3% at $100.12

Jefferies cuts PT to $116 from $135, maintains "hold" rating

New PT represents 13.2% upside to stock's last close

"Near-term uncertainty in key end markets like biopharma, China, and business units like nucleic acid solutions division leaves us cautious on the company's ability to outperform against the current setup," Jefferies says

Brokerage says co feels "pretty good" on tariff dynamics for contract drug manufacturing business, as most deals are structured so that costs for raw materials are passed along i.e., little threat to A's cost profile

Jefferies sees limited potential for valuation increases until there's clearer visibility into normal growth returning in 2025 and beyond

Nine of 21 brokerages rate stock "buy" or higher, 12 "hold"; median PT is $142.41 - LSEG data

Including session's moves, stock down 25.2% YTD